Molecular imaging using nanobodies: A case study

Methods in Molecular Biology

Volumn 911, Issue , 2012, Pages 559-567

  Devoogdt, Nick ^a   Xavier, Catarina ^a   Hernot, Sophie ^a   Vaneycken, Ilse ^a   D'Huyvetter, Matthias ^a   De Vos, Jens ^a,b   Massa, Sam ^a,b   De Baetselier, Patrick ^a,b   Caveliers, Vicky ^a,c   Lahoutte, Tony ^a,c  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Biodistribution; Fluorescence; Molecular imaging; PET; Radiochemistry; Radionuclide; SPECT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; NANOBODY; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; ZIRCONIUM 89;

ARTICLE; BREAST CANCER; COMPUTER PROGRAM; FLUORESCENCE; HUMAN; MOLECULAR IMAGING; NONHUMAN; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

EID: 84934443119     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-968-6_35     Document Type: Article

References (21)

1. Pysz MA, Gambhir SS, Willmann JK (2010) Molecular imaging: current status and emerging strategies. Clin Radiol 65:500-516
2. Gainkam LO, Huang L, Caveliers V et al (2008) Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 49:788-795
3. Vaneycken I, Devoogdt N, Van Gamer N, Vincke C, Xavier C, Nennery U, Muyldermans S, Lahoutte T, Caveliers V (2011) Pre-clinical screening of anti-HER2 Nanobodies for molecular imaging of breast cancer. FASEB J 25: 2433-2446
4. Van Bockstaele F, Holz JB, Revets H (2009) The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 10:1212-1224
5. Hmila I, Saerens D, Ben Abderrazek R, Vincke C, Abidi N, Benlasfar Z, Govaert J, El Ayeb M, Bouhaouala-Zahar B, Muyldermans S (2010) A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J 24:3479-3489
6. Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, Priem S, Lauwereys M, Casteels P, Van Bockstaele F, Verschueren K, Stanssens P, Baumeister J, Holz JB (2011) Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to currently marketed antiplatelet drugs. Blood 118:757-765
7. Van de Broek B, Devoogdt N, D'Hollander A, Gijs HL, Jans K, Lagae L, Muyldermans S, Maes G, Borghs G (2011) specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano 5:4319-4328
8. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, Van Bergenen Henegouwen PM (2007) efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 56:303-317
9. Conrath K, Lauwereys M, Wyns L, Muyldermans S (2001) Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 276:7346-7350
10. Hmila I, Abdallah RB, Saerens D, Benlasfar Z, Conrath K, Ayeb ME, Muyldermans S, Bouhaouala-Zahar B (2008) VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol Immunol 45:3847-3856
11. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA (2008) Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 7:2288-2297
12. Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, Stichelberger A, Egli A, Abram U, Mach JP, Pluckthun A, Schubiger PA (1999) Stable one-step technetium-99 m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 17:897-901
13. Vaneycken I, Govaert J, Vincke C, Caveliers V, Lahoutte T, De Baetselier P, Raes G, Bossuyt A, Muyldermans S, Devoogdt N (2010) In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med 51:1099-1106
14. Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, Bossuyt A, Revets H, Lahoutte T (2008) SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 10:167-175
15. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K (2009) General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284:3273-3284
16. Weissleder R, Ntziachristos V (2003) Shedding light onto live molecular targets. Nat Med 9:123-128
17. Gainkam LO, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O, Muyldermans S, Bossuyt A, Lahoutte T (2011) Localization, mechanism and reduction of renal retention of technetium-99 m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging 6:85-92
18. Cortez-Retamozo V, Lahoutte T, Caveliers V, Tchouate-Gainkam O, Hernot S, Packeu A, De Vos F, Vanhove C, Muyldermans S, De Baetselier P, Revets H (2008) 99mTc-labeled nanobodies: a new type of targeted probes for imaging antigen expression. Curr Radiopharm 1:37-41
19. Tchouate LO, Gainkam M, Keyaerts V, Caveliers N, Devoogdt C, Vanhove LV, Grunsven SM, Lahoutte T (2011) Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. Mol Imaging Biol 13(5):940-948
20. De Groeve K, Deschacht N, De Koninck C, Caveliers V, Lahoutte T, Devoogdt N, Muyldermans S, De Baetselier P, Raes G (2010) Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med 51:782-789
21. Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN (2009) Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immu-noPET imaging. J Nucl Med 50:974-981